Trial Profile
Open-label Study of Safety, Tolerability and Pharmacokinetics of Multiple Doses of BI-CON-02 in Patients With HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab-conjugate (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors BioIntegrator
- 14 Jul 2019 Status changed from recruiting to discontinued.
- 01 Mar 2017 New trial record